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Case Report
Systemic Mastocytosis: a Rare Entity
Naveen Naz Syed, Bushra Moiz
Section of Haematology, Department of Pathology and Microbiology, Aga Khan University Hospital, Karachi.

Abstract

mastocytosis).2 Systemic mastocytosis may show either an
indolent or an aggressive clinical course.

An 18 year old female presented with generalized
maculopapular rash and headaches. The skin and bone marrow biopsy revealed numerous mast cells which stained
metachromatically with giemsa and toludine blue stains and
showed positivity with CD68 and CD117 on immuno-histochemistry. Her clinical presentation and laboratory findings
were consistent with the diagnosis of indolent systemic
mastocytosis. Because of the benign course of the disease,
patient was offered only anti-histamine drugs that were
quite successful in alleviating her symptoms.

Systemic mastocytosis is a rare entity and its exact
incidence is not known. However, it has been reported to be
present in one of 1,000 to 8,000 patients evaluated at a dermatology clinic.4 No case has ever been reported from
Pakistan to the best of our knowledge. Here in, we report a
case of indolent systemic mastocytosis who presented with
skin lesions.

Introduction

Case Report

Mastocytosis is a heterogeneous group of diseases
characterized by abnormal growth and accumulation of
mast cells in one or more organ system.1 The most frequently involved tissue is the skin (cutaneous mastocytosis) but
bone marrow, gastrointestinal tract, liver, spleen and
lymph nodes may be implicated to varying extent
depending on the variant of the disease (systemic

An 18 year old female presented with complaint of
generalized maculopapular rash. Skin lesions started on her
trunk at sixth day of her life, later involved whole body
sparing her palms, sole and scalp. There was no complaint
of itching. Since three years, she was suffering from periodic exacerbations in skin lesions especially on her face which
was the main reason for consultation. Although she

338

In indolent systemic mastocytosis, patients present
with maculopapular skin lesions and a good prognosis.3
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did not experience gastritis, flushing, diarrhoea or
syncope, yet she was having on and off complaints of
headache since past few years. Her parents and the remaining six siblings were not affected. Besides her skin lesions,
rest of the physical examination was normal.
Considering her presentation, she was diagnosed
clinically to be suffering from urticaria pigmentosa. The
histo-pathological studies of skin biopsy of lesions later
showed diffuse infiltration of the dermis with mast cells
therefore, a diagnosis of cutaneous mastocytosis was made.
She was subsequently advised for bone marrow examination to rule out involvement. Her complete blood count was
unremarkable. Bone marrow aspirate was a normo-cellular
specimen with normal haemopoietic cells and prominent
mast cells. The sections of bone marrow biopsy, stained
with haematoxylin and eosin (H&E), showed loosely
arranged mast cells that were difficult to recognize.
However, subsequent staining with Giemsa (Figure 1) and
toulidene-blue stained them metachromatically. Silver
impregnation and trichrome

Figure 1: Bone marrow biopsy X100, demonstrating mast cells highlighted with giemsa stain.

staining showed normal pattern of reticulin and collagen
fibers. Immuno-histochemistry was done which showed
positivity with CD117 and CD68 (Figure 2) in the mast
cells.
On the basis of clinical presentation and laboratory
investigations, we diagnosed our patient to be suffering
from indolent systemic mastocytosis. She was started on
anti-histamine drugs that were quite successful in alleviating her symptoms.

Discussion
Mastocytosis is an infrequent condition, and
although a number of classification schemes have been put
forward for mast cell disease but none have been universally accepted. The WHO classification of mast cell disease
seems to be more practical and useful for characterizing the
disorder.5
Cutaneous mastocytosis has a relatively benign
course and is seen more commonly in children. The systemic mastocytosis which usually affects adults has a clinical spectrum ranging from indolent course to aggressive and
fatal mast cell leukaemia.6 Therefore, symptoms in systemic mastocytosis are also very variable. They may result
either from mast cell derived mediators (such as histamine,
leukotrienes and prostaglandin) or from destructive infiltration of mast cells.7 Our patient had suffered from prolonged
indolent course of urticaria pigmentosa since her early
childhood and only recently she had developed headaches,
representing excess histamine release.
In indolent systemic mastocytosis, the mast cells
may form loose aggregates in bone marrow and become difficult to recognize without special immunohistochemical
stains.8 They may be paratrabecular, perivascular or randomly distributed, with or without fibrosis.9 In our case,
bone marrow had loosely scattered mast cells which highlighted with giemsa stain and expressed CD 117 and CD68,
along with normal haemopoietic tissue. This, confirmed the
diagnosis of indolent systemic mastocytosis. However,
tryptase, CD2 and CD25 which are considered to be reliable
immunohistochemical markers in the diagnosis of systemic
mastocytosis10 were not utilized because of the non availability of these markers.
Although, the patient had relatively benign systemic
mastocytosis, appropriate treatment should be sought due to
great psychosocial concerns particularly in case of females.
She was prescribed anti-histamine drugs that were quite
effective in reducing her symptoms.
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